{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:54:26Z","timestamp":1787237666245,"version":"build-2736575974"},"reference-count":27,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,2,3]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Inhaled corticosteroids (ICS) achieve disease control in the majority of asthmatic patients, although adherence to prescribed ICS is often poor. Patients with severe eosinophilic asthma may require treatment with oral corticosteroids (OCS) and\/or biologic agents such as mepolizumab. It is unknown if ICS adherence changes on, or alters clinical response to, biologic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined ICS adherence and clinical outcomes in OCS-dependent severe eosinophilic asthma patients who completed 1\u2005year of mepolizumab therapy. The ICS medicines possession ratio (MPR) was calculated (the number of doses of ICS issued on prescription\/expected number) for the year before and the year after biologic initiation. Good adherence was defined as MPR &gt;0.75, intermediate 0.74\u20130.51 and poor &lt;0.5. We examined outcomes after 12\u2005months of biologic therapy, including OCS reduction and annualised exacerbation rate (AER), stratified by adherence to ICS on mepolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 109 patients commencing mepolizumab, 91 who had completed 12\u2005months of treatment were included in the final analysis. While receiving mepolizumab, 68% had good ICS adherence, with 16 (18%) having poor ICS adherence. ICS use within the cohort remained similar before (MPR 0.81\u00b10.32) and during mepolizumab treatment (0.82\u00b10.32; p=0.78). Patients with good adherence had greater reductions in OCS dose (median (interquartile range) OCS reduction 100 (74\u2013100)%\n                      <jats:italic>versus<\/jats:italic>\n                      60 (27\u2013100)%; p=0.031) and exacerbations (AER change \u22122.1\u00b13.1\n                      <jats:italic>versus<\/jats:italic>\n                      0.3\u00b12.5; p=0.011) than those with poor adherence. Good ICS adherence predicted the likelihood of stopping maintenance OCS (adjusted OR 3.19, 95% CI 1.02\u20139.94; p=0.045).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICS nonadherence is common in severe eosinophilic asthma patients receiving mepolizumab, and is associated with a lesser reduction in OCS requirements and AER.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.02259-2019","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T11:25:18Z","timestamp":1581679518000},"page":"1902259","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["Adherence to inhaled corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma"],"prefix":"10.1183","volume":"55","author":[{"given":"Gr\u00e1inne","family":"d'Ancona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cris","family":"Roxas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Dhariwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Nanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-868X","authenticated-orcid":false,"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"2024102101242703000_55.5.1902259.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5800.585"},{"key":"2024102101242703000_55.5.1902259.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024102101242703000_55.5.1902259.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00703-2018"},{"key":"2024102101242703000_55.5.1902259.4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84144"},{"key":"2024102101242703000_55.5.1902259.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024102101242703000_55.5.1902259.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2024102101242703000_55.5.1902259.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024102101242703000_55.5.1902259.8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102101242703000_55.5.1902259.9","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2019. Available from: http:\/\/ginasthma.org"},{"key":"2024102101242703000_55.5.1902259.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200902-0166OC"},{"key":"2024102101242703000_55.5.1902259.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01836-2017"},{"key":"2024102101242703000_55.5.1902259.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201096"},{"key":"2024102101242703000_55.5.1902259.13","unstructured":"National Institute for Health and Care Guidance (NICE). Mepolizumab for Treating Severe Refractory Eosinophilic Asthma. 2017. www.nice.org.uk\/guidance\/ta431\/resources\/mepolizumab-for-treating-severe-refractory-eosinophilic-asthma-82604719119301"},{"key":"2024102101242703000_55.5.1902259.14","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14a08.x"},{"key":"2024102101242703000_55.5.1902259.15","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14d29.x"},{"key":"2024102101242703000_55.5.1902259.16","doi-asserted-by":"crossref","first-page":"217047","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"},{"key":"2024102101242703000_55.5.1902259.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01126-2017"},{"key":"2024102101242703000_55.5.1902259.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01025-2018"},{"key":"2024102101242703000_55.5.1902259.19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.anai.2014.10.012","article-title":"Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy","volume":"114","author":"Hendeles","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102101242703000_55.5.1902259.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-789OC"},{"key":"2024102101242703000_55.5.1902259.21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101242703000_55.5.1902259.22","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024102101242703000_55.5.1902259.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2007.07.016"},{"key":"2024102101242703000_55.5.1902259.24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00172114"},{"key":"2024102101242703000_55.5.1902259.25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.201806-1182OC","article-title":"Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma","volume":"199","author":"Heaney","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101242703000_55.5.1902259.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0587OC"},{"key":"2024102101242703000_55.5.1902259.27","doi-asserted-by":"crossref","first-page":"e015367","DOI":"10.1136\/bmjopen-2016-015367","article-title":"In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making? A protocol for a randomised controlled trial","volume":"7","author":"Mokoka","year":"2017","journal-title":"BMJ Open"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02259-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:29:04Z","timestamp":1740364144000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02259-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1183\/13993003.02259-2019"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02259-2019","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}